Comparative Pharmacology
Head-to-head clinical analysis: DALGAN versus OLINVYK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALGAN versus OLINVYK.
DALGAN vs OLINVYK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Oliceridine is a G protein-biased μ-opioid receptor agonist. It preferentially activates the G protein pathway (associated with analgesia) over β-arrestin recruitment (associated with opioid-related adverse effects like respiratory depression and gastrointestinal dysfunction).
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
Initial adult dose: 1.5 mg intravenously (IV) every 3 to 6 hours as needed. May be titrated in increments of 0.75 mg to 1.5 mg every 3 to 6 hours. Maximum single dose: 4.5 mg. Maximum daily dose: 27 mg.
None Documented
None Documented
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Terminal elimination half-life is approximately 26–29 hours, supporting once-daily dosing in chronic pain
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Primarily renal (approximately 90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic